Rodman

Rodman v. Otsuka America Pharmaceutical, Inc.

Good Law
United States District Court, Northern District of CaliforniaMay 18, 20203:18-cv-03732California7,285 words

Opinion

trial_court Opinion

1 2 3 4 UNITED STATES DISTRICT COURT 5 NORTHERN DISTRICT OF CALIFORNIA 6 7 INA ANN RODMAN, Case No. 18-cv-03732-WHO

8 Plaintiff, ORDER GRANTING DEFENDANT’S

MOTION FOR SUMMARY

9 v. JUDGMENT

10 OTSUKA AMERICA Re: Dkt. No. 65, 66, 67, 68

PHARMACEUTICAL, INC.,

11 Defendant. 12

13 In this product liability suit, plaintiff Ina Rodman alleges that she suffers from a movement 14 disorder known as Tardive Dyskinesia (“TD”) as a result of ingesting the prescription 15 antipsychotic medication Abilify. She brings failure to warn and design defect claims against 16 defendant Otsuka America Pharmaceutical, Inc. (“Otsuka”). Before me are cross-motions for 17 summary judgment on the failure to warn claim, along with Otsuka’s motion for summary 18 judgment on the design defect claim. Both parties also move to exclude portions of expert 19 testimony. 20 Rodman’s case founders on a lack of proof. For the reasons set forth below, I GRANT 21 summary judgment in favor of Otsuka on all three theories of Rodman’s failure to…

Sign in to read the full opinion

Create a free account to read the complete opinion text, citation history, and good-law status for this case.

Rodman · N.D. California · 2020 | Caselegis